ProQR Therapeutics (PRQR) AGM 2024 summary

Opening remarks and agenda

• Event began with an introduction and agenda overview, including presentations on strategic business updates, scientific platform progress, and pipeline programs, followed by a Q&A session with analysts and investors.

Strategic initiatives and plans

• Focused on advancing the Axiomer ADAR-mediated RNA editing platform, with up to four clinical trial readouts expected over the next two years.

• Announced expansion of the Rett Syndrome program, supported by $8.1 million in new funding from the Rett Syndrome Research Trust.

• Plans to add two new clinical programs to the pipeline each year, targeting both rare and common diseases.

• Ongoing strategic partnerships, notably with Eli Lilly, generating milestone payments and collaborative R&D.

Financial performance review

• Reported a cash position of €89.4 million, with an additional $82.1 million raised in October, extending operational runway into mid-2027.

• Financial guidance does not include potential future milestone payments from partnerships.